TLX
Telix Pharmaceuticals LtdPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 28 to Apr 29 ▲ 2 days of insider buys: $996.7K by 1 insider, avg $14.67
- Sep 1 ▲ Telix Pharmaceuticals completed enrollment of 350 patients in the Ph…
- Sep 1 ▲ Telix completed enrollment (350 patients) in the Phase 3 BiPASS stud…
- Sep 7 ▲ 1 insider buy $20.0K at $9.66
- Sep 14 ▲ Telix Pharmaceuticals announced FDA approval of Pixclara (floretyros…
- Sep 14 FDA: FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
- Sep 14 ▲ Telix Pharmaceuticals announced FDA approval of Pixclara® (floretyro…
- Sep 15 ▼ Short interest jumps 33.1% to 352.5K
- Sep 21 ▲ Telix Pharmaceuticals announced a transformational merger with ITM I…
- Sep 21 ▲ Telix announces a transformational merger with ITM Isotope Technolog…
- Sep 30 ▲ Telix Pharmaceuticals announced that the FDA granted Fast Track desi…
- Oct 20 ▲ Telix reported Q3 2026 group revenue of $245M (+19% YoY), with Preci…
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $1.0M. No open-market sales.
- InstitutionsBULLISH
Q3 2026: 9 added (0 new), 4 trimmed or exited.
- Short sellersCOVERING
Short interest −23.3% to 270.6K shares. 1.0 days to cover, ≈0.1% of shares.
- TrendDOWNTREND
16% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BLAIR WILLIAM & CO/IL | DOUBLED | $5.3M |
| UBS Group AG | TRIM | $1.1M |
| Orion Porfolio Solutions, LLC | DOUBLED | $534.9K |
| MARSHALL WACE, LLP | NEAR_EXIT | $411.4K |
| MORGAN STANLEY | NEAR_EXIT | $328.5K |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $312.6K |
| OSAIC HOLDINGS, INC. | DOUBLED | $151.3K |
| NATIXIS | TRIM | $81.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Oct 2026| Date | Firm | Rating |
|---|---|---|
| Oct 21, 2026 | Wedbush REITERATE | Outperform |
| Sep 25, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 23, 2026 | Wedbush REITERATE | Outperform |
| Sep 15, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 14, 2026 | Wedbush REITERATE | Outperform |
| Sep 2, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Smith Darren Charlton Group Chief Financial Officer Sep 7, 2026 | BUY | $20.0K |
Behrenbruch Christian MD & Group CEO Apr 29, 2026 | BUY | $497.2K |
Behrenbruch Christian MD & Group CEO Apr 28, 2026 | BUY | $499.6K |
Smith Darren Charlton Group Chief Financial Officer Mar 29, 2026 | EXERCISE | 1,111 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
12 filings · 15 press releases · 9 bullish · 0 bearish · 3 neutral- NEUTRAL 6-KOct 29, 2026
Telix Pharmaceuticals filed a Notice of General Meeting seeking shareholder approval to issue up…
The shareholder vote on December 1, 2026 is the key near-term catalyst. Approval of the upfront share issuance is a condition precedent to closing. Monitor regulatory developments for ITM-11 (NDA…
- NEUTRAL 6-KOct 20, 2026
Telix reported Q3 2026 group revenue of US$245 million, up 19% YoY, driven by 30% growth in…
Monitor the ITM merger shareholder vote on December 1, 2026, and the upcoming BLA resubmission for Zircaix. Revenue growth trajectory and Pixclara commercial ramp will be key to FY guidance…
- BULLISH PRESS-RELEASEOct 20, 2026
Telix reported Q3 2026 group revenue of $245M (+19% YoY), with Precision Medicine revenue up 30%…
Monitor the December 1, 2026 shareholder vote on the ITM merger; approval would create a vertically integrated radiopharmaceutical leader. Also watch for the TLX250-Px BLA resubmission and Pixclara…
- BULLISH 6-KSep 29, 2026
Telix Pharmaceuticals announced that the FDA granted Fast Track designation for its BiPASS…
Fast Track designation de-risks the regulatory pathway and signals FDA engagement, but the key catalyst remains the NDA submission and eventual approval. Monitor for NDA filing timing and any Phase…
All TLX filing & press-release reports (27)
- 6-K reportOct 29, 2026
- 6-K reportOct 20, 2026
- PRESS-RELEASE reportOct 20, 2026
- 6-K reportSep 29, 2026
- 6-K reportSep 21, 2026
- PRESS-RELEASE reportSep 20, 2026
- 6-K reportSep 14, 2026
- PRESS-RELEASE reportSep 14, 2026
- 6-K reportSep 1, 2026
- PRESS-RELEASE reportSep 1, 2026
- 6-K reportAug 19, 2026
- PRESS-RELEASE reportAug 19, 2026
- PRESS-RELEASE reportJul 30, 2026
- PRESS-RELEASE reportJul 21, 2026
- 6-K reportJul 21, 2026
- PRESS-RELEASE reportJul 20, 2026
- PRESS-RELEASE reportJul 20, 2026
- PRESS-RELEASE reportJul 15, 2026
- PRESS-RELEASE reportJul 1, 2026
- PRESS-RELEASE reportJun 2, 2026
- PRESS-RELEASE reportJun 1, 2026
- PRESS-RELEASE reportMay 18, 2026
- PRESS-RELEASE reportMay 15, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportApr 13, 2026